Rapport Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
RAPP$26.07+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $39,314 | $70,169 |
| Short-term investments | 281,347 | 77,309 |
| Restricted cash | 105 | 85 |
| Prepaid expenses and other current assets | 5,173 | 3,309 |
| Total current assets | 325,939 | 150,872 |
| Property and equipment, net | 3,409 | 1,916 |
| Operating lease right of use asset, net | 1,607 | 2,084 |
| Other assets | 189 | 551 |
| Total assets | $331,144 | $155,423 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable (1) | $1,323 | $2,502 |
| Accrued expenses and other current liabilities (1) | 5,056 | 5,631 |
| Operating lease liability | 720 | 670 |
| Total current liabilities | 7,099 | 8,803 |
| Series B preferred stock tranche right liability | — | 4,200 |
| Operating lease liability, net of current portion | 931 | 1,476 |
| Total liabilities | 8,030 | 14,479 |
| Commitments and contingencies (Note 11) | ||
| Series A convertible preferred stock, $0.001 par value; zero and 100,182,354 shares authorized as of September 30, 2024 and December 31, 2023, respectively; zero shares and 100,182,354 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation preference of zero and $100,182 as of September 30, 2024 and December 31, 2023, respectively | — | 89,487 |
| Series B convertible preferred stock, $0.001 par value; zero and 89,431,030 shares authorized as of September 30, 2024 and December 31, 2023, respectively; zero and 51,273,790 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively; liquidation preference of zero and $86,000 as of September 30, 2024 and December 31, 2023, respectively | — | 77,091 |
| Stockholders’ equity (deficit) | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares and zero shares authorized at September 30, 2024 and December 31, 2023, respectively; zero shares issued and outstanding at both September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares and 250,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 36,576,457 shares and 4,170,817 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 36 | 4 |
| Additional paid-in capital | 426,443 | 19,796 |
| Accumulated other comprehensive income | 400 | 4 |
| Accumulated deficit | (103,765) | (45,438) |
| Total stockholders’ equity (deficit) | 323,114 | (25,634) |
| Total liabilities, convertible preferred stock, and stockholders’ equity | $331,144 | $155,423 |
(1)
Includes related party amounts ofzero and$0.2 million (accounts payable) andless than $0.1 million andzero (accrued expenses) as of September 30, 2024 and December 31, 2023, respectively (see Notes 5 and 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.